S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Hyundai and Strava Challenge Hits Record 20 Million Miles for Charity

More than 150,000 participants logged nearly 20 million miles in September, shattering Strava’s all-time distance record. The massive effort, part of Hyundai’s “The Mark of a Warrior” campaign, successfully raised $3 million for Hyundai Hope on Wheels to fund critical pediatric cancer research and treatment programs.

Hyundai and Strava Challenge Hits Record 20 Million Miles for Charity
Photo: Bio & News

The Miles for the Warriors Challenge launched on September 2 to coincide with Childhood Cancer Awareness Month. Initially aiming for a 400,000-mile target with a $1 million donation, the community reached that goal within 24 hours. Hyundai responded by twice increasing its targets, ultimately committing $3 million as the collective distance reached 19,959,136 miles. Participants contributed via running, walking, cycling, swimming, and hiking, resulting in over 2.6 million individual activity logs.

Beyond the raw distance, the initiative garnered significant digital engagement, reaching 2.6 million people across social media and the Strava platform. Sean Gilpin, chief marketing officer at Hyundai Motor America, noted the extraordinary scale of support for families affected by the disease. While the primary challenge has concluded, the manufacturer continues its fundraising through December 31, 2026, pledging an additional $36 per qualifying social media post to support the nonprofit’s mission.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!